Industry Outlook

The insomnia treatment drugs market is set to reach US$ 4,332.4 Mn by 2026 from US$ 2,689.6 Mn in 2017 highlighting balanced growth at a compound annual growth rate (CAGR) of 5.5% during the forecast period from 2018 to 2026. As per the research citing of United Nations (UN) by 2030 the geriatric population suffering with insomnia is going to rise by 56%. Insomnia is caused by factors such as stress, addiction, irregular circadian rhythm, chronic pain etc. The major concern of insomnia is it remains undiagnosed, and lack of early medical intervention results in serious health concern. Pharmaceutical companies are investing in the formulation research and development segment to reduce the adverse effects associated with the medicines prescribed for insomnia treatment.

Melatonin is recommended in patients suffering with circadian rhythm disorder and lack of sleep due to jet lag. In developing countries such as China and India the dietary supplements such as valerian roots, chamomile, passionflower tea etc., are finding prominence in treating insomnia effectively. Domicile of key players pioneering in the treatment of insomnia and growing health awareness makes North America the global leader in the insomnia treatment drugs market. Increasing geriatric population, effective insomnia diagnosis and developing healthcare infrastructure propels the market growth in Asia Pacific region.

Increasing health awareness regarding insomnia treatment to propel the prescription sleep aids market

As if now the prescription sleep aids are commanding the insomnia treatment drugs market. Physicians throughout the globe are prescribing benzodiazepines, antidepressant and orexin antagonist to patients suffering with sleep disorder. Benzodiazepine such as alprazolam, diazepam, and clonazepam are prescribed in patients suffering with insomnia due to anxiety. Antidepressant are given in combination with zolpidem (sedative) in patients suffering with insomnia due to neuropsychiatric ailment.  The challenges faced by the prescription sleep aid drugs are the severe adverse effects associated with it such as withdrawal symptoms, psychosis and seizures. Over the counter sleep aids will be projecting excellent market growth during the forecast period owing to rising popularity in developing countries, low cost and no adverse effects.

Increasing geriatric population suffering with insomnia to drive the insomnia treatment drugs market in Asia Pacific region

Currently North America is dominating the regional segment for insomnia treatment drugs market and accounts for approximately 55% of the total market share. The key drivers responsible for the dominance of North America are presence of pharmaceutical companies such as Sanofi S.A., and F.Hoffman La-Roche AG etc., catering the medication supply for insomnia treatment. Existence of well-developed healthcare infrastructure and affordable reimbursement scenario for insomnia treatment drugs propel the market growth in North America. Asia Pacific is anticipated to showcase remarkable growth during the forecast period 2018 to 2026. Increasing geriatric population suffering with sleep disorder and rising mental health awareness is having a positive impact on the insomnia treatment drugs market in Asia Pacific region. Supportive regulatory environment and increasing funding in the healthcare segment by government and pharmaceutical companies to support the market growth in Latin America and Middle East and Africa.

Market assessment is performed to understand the latest market trend in order to cater the quantitative analysis for insomnia treatment drugs market. Merger and acquisition and strategic decision between the pharmaceutical industry and research academia is highlighted in the report to understand the medicinal requirement of the patients suffering with insomnia. Product portfolio provides valuable insights regarding the different brands of medication available for the treatment of insomnia. The major players actively engaged in the manufacturing of insomnia treatment drugs are F.Hoffman La-Roche AG, Merck & Co. Inc., Mylan N.V., Pfizer, Inc., Pernix Therapeutics, Sanofi S.A., Takeda Pharmaceutical Company Ltd., Sumitomo Dainippon Pharma Co., Ltd, Teva Pharmaceutical Industries Ltd. and Vanda Pharmaceuticals, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Insomnia Treatment Drugs market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Insomnia Treatment Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Insomnia Treatment Drugs market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Insomnia Treatment Drugs market?
• Which is the largest regional market for Insomnia Treatment Drugs market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Insomnia Treatment Drugs market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Insomnia Treatment Drugs market worldwide?